Literature DB >> 10805089

Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein.

A Probst1, J Götz, K H Wiederhold, M Tolnay, C Mistl, A L Jaton, M Hong, T Ishihara, V M Lee, J Q Trojanowski, R Jakes, R A Crowther, M G Spillantini, K Bürki, M Goedert.   

Abstract

Coding region and intronic mutations in the tau gene cause frontotemporal dementia and parkinsonism linked to chromosome 17. Some of these mutations lead to an overproduction of tau isoforms with four microtubule-binding repeats. Here we have expressed the longest four-repeat human brain tau isoform in transgenic mice under the control of the murine Thy1 promoter. Transgenic mice aged 3 weeks to 25 months overexpressed human tau protein in nerve cells of brain and spinal cord. Numerous abnormal, tau-immunoreactive nerve cell bodies and dendrites were seen. In addition, large numbers of pathologically enlarged axons containing neurofilament- and tau-immunoreactive spheroids were present, especially in spinal cord. Signs of Wallerian degeneration and neurogenic muscle atrophy were observed. When motor function was tested, transgenic mice showed signs of muscle weakness. Taken together, these findings demonstrate that overexpression of human four-repeat tau leads to a central and peripheral axonopathy that results in nerve cell dysfunction and amyotrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805089     DOI: 10.1007/s004010051148

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  109 in total

Review 1.  Frontotemporal dementia and tauopathy.

Authors:  Y Yoshiyama; V M Lee; J Q Trojanowski
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

Review 3.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

Authors:  H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz
Journal:  Neuroscience       Date:  2010-04-29       Impact factor: 3.590

Review 5.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

6.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

7.  Evaluation of the mouse TgTP6.3 tauGFP transgene as a lineage marker in chimeras.

Authors:  Gillian E MacKay; Margaret A Keighren; Linda Wilson; Thomas Pratt; Jean H Flockhart; John O Mason; David J Price; John D West
Journal:  J Anat       Date:  2005-01       Impact factor: 2.610

8.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

9.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 10.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.